meta:
  schema_version: '1.0'
  generated_by: Dawn (literature curation)
  last_updated: '2026-02-13'
  compatible_engine: cellswarm>=2.0
pathway_id: CTLA4_CD28
pathway_name: CTLA-4/CD28 Costimulation Checkpoint
category: immune_checkpoint
kegg_id: hsa04514
components:
  receptors:
  - CTLA4
  - CD28
  ligands:
  - CD80
  - CD86
  downstream:
  - PI3K
  - AKT
  - PP2A
  - SHP2
  transcription_factors:
  - NFAT
  - AP1
  - NFKB
  key_genes:
  - CTLA4
  - CD28
  - CD80
  - CD86
signal_fields_affected:
- IL2
cell_type_effects:
  CD8_T:
    when_active: CTLA-4 outcompetes CD28 for B7 ligands, blocking costimulation. Inhibits
      early T cell activation and IL-2 production.
    behavioral_mapping:
      attack: -0.2
      proliferate: -0.25
      rest: 0.2
      signal: -0.15
    state_effects:
      activation: -0.25
      cytotoxicity: -0.15
  Treg:
    when_active: CTLA-4 is constitutively expressed on Tregs and essential for their
      suppressive function. Captures B7 ligands via trans-endocytosis.
    behavioral_mapping:
      suppress: 0.25
      signal: 0.1
    state_effects:
      suppressive_activity: 0.2
  Tumor:
    when_active: 'Indirect effect: CTLA-4 mediated T cell suppression benefits tumor
      survival.'
    behavioral_mapping:
      evade: 0.15
    state_effects:
      immune_evasion: 0.1
  Macrophage:
    when_active: CTLA-4 blockade enhances macrophage-mediated ADCC via Fc receptor
      engagement.
    behavioral_mapping:
      phagocytose: 0.05
    state_effects: {}
  NK:
    when_active: Minimal direct effect on NK cells.
    behavioral_mapping: {}
    state_effects: {}
  B_cell:
    when_active: CTLA-4 on B cells modulates germinal center responses.
    behavioral_mapping:
      signal: -0.05
    state_effects: {}
crosstalk:
- pathway: PD1_PDL1
  type: synergistic_inhibition
  description: CTLA-4 acts early (priming), PD-1 acts late (effector phase); complementary
    inhibition
- pathway: IL2_STAT5
  type: antagonistic
  description: CTLA-4 suppresses IL-2 production, reducing STAT5 signaling
- pathway: TCR_signaling
  type: antagonistic
  description: CTLA-4 competes with CD28 for costimulatory ligands
targeted_by:
- drug_id: ipilimumab
  mechanism: Anti-CTLA-4 monoclonal antibody
- drug_id: tremelimumab
  mechanism: Anti-CTLA-4 monoclonal antibody
references:
- description: CTLA-4 inhibitory function in T cells. Leach et al. Science 1996
  pmid: '8596936'
  pmid_verified: true
- description: CTLA-4 is essential for Treg-mediated suppression. Wing et al. Science
    2008
  pmid: '18845758'
  pmid_verified: true
data_calibration:
  source: GSE176078 TNBC scRNA-seq (CellChat-lite)
  n_cells: 997
  communication_strength: 0.0675
  max_communication_strength: 0.1982
  n_active_pairs: 6
  top_interactions:
  - sender: Macrophage
    receiver: Treg
    ligand: CD86
    receptor: CTLA4
    probability: 0.1982
  - sender: Macrophage
    receiver: CD8_T
    ligand: CD86
    receptor: CTLA4
    probability: 0.1122
  - sender: Macrophage
    receiver: Treg
    ligand: CD80
    receptor: CTLA4
    probability: 0.046
  - sender: Macrophage
    receiver: CD8_T
    ligand: CD80
    receptor: CTLA4
    probability: 0.0325
  - sender: B_cell
    receiver: Treg
    ligand: CD86
    receptor: CTLA4
    probability: 0.0094
